Back to companies

Mayne Pharma Group Ltd: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Mayne Pharma Group Ltd (Mayne Pharma), is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company offers products such as astrix capsules, Eryc capsules, kapanol capsules, lozanoc capsules, amethia tablets, amiodarone hydrochloride tablets, azurette tablets, budesonide capsules, camila tablets and clonidine transdermal patches, among others. It also offers contract development and CDMO services such as pharmaceutical development, analytical testing and commercial manufacturing. The company operates in Australia and the US, the UK and Canada. Mayne Pharma is headquartered in Adelaide, South Australia, Australia.

Gain a 360-degree view of Mayne Pharma Group Ltd and make more informed decisions for your business Gain a 360-degree view of Mayne Pharma Group Ltd and make more informed decisions for your business Contact Us
Headquarters Australia

Address 1538 Main North Rd, Adelaide, South Australia, 5106


Telephone 61 8 82092666

No of Employees 900

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange MYX (ASX)

Revenue (2022) $132.0M 20.7% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 141.7% (2022 vs 2021)

Market Cap* $267.7M

Net Profit Margin (2022) XYZ 134.5% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Mayne Pharma Group Ltd premium industry data and analytics

90+

Clinical Trials

Determine Mayne Pharma Group Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

60+

Marketed Drugs

Understand Mayne Pharma Group Ltd’s commercialized product portfolio to stay one step ahead of the market.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Mayne Pharma Group Ltd’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Mayne Pharma Group Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

16+

Pipeline Drugs

Identify which of Mayne Pharma Group Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Mayne Pharma Group Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Astrix Capsules Contract Services Astrix
Eryc Capsules Product Development Doryx
Kapanol Capsules Kadian
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Mayne Pharma Group Ltd portfolio and identify potential areas for collaboration Understand Mayne Pharma Group Ltd portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In September, the company's subsidiary entered into an asset purchase agreement to acquire the global rights to RHOFADE from Novan, Inc. and EPI Health, LLC.
2023 Divestiture In April, the company sold its US retail generics portfolio to Dr Reddy’s Laboratories.
2022 Contracts/Agreements In December, the company signed an exclusive license agreement with TherapeuticsMD, Inc for three branded women’s health products and a portfolio of prenatal vitamins in the US.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters Mayne Pharma Group Ltd CSL Ltd Sigma Healthcare Ltd Cryosite Ltd IDT Australia Ltd
Headquarters Australia Australia Australia Australia Australia
City Adelaide Melbourne Melbourne Sydney Melbourne
State/Province South Australia Victoria Victoria New South Wales Victoria
No. of Employees 900 32,065 156 34 156
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Frank Condella Chairman Executive Board 2021 68
Shawn Patrick O’Brien Chief Executive Officer; Managing Director; Director Executive Board 2022 -
Aaron Gray Chief Financial Officer Senior Management 2022 -
Brant Schofield Executive Vice President - Corporate Development Senior Management - -
Laura Loftus Secretary; Associate General Counsel Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Mayne Pharma Group Ltd key executives to enhance your sales strategy Gain insight into Mayne Pharma Group Ltd key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer